The role of different viral biomarkers on the management of chronic hepatitis B
Clinical and Molecular Hepatology · 2023
DOI: 10.3350/cmh.2022.0448 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Lung-Yi Mak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Hong Kong. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Gilead Sciences, Assembly Biosciences, Aligos Therapeutics.
Abstract (Originalsprache)
Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for ≥6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Hong Kong.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
Förderung
- Gilead Sciences
- Assembly Biosciences
- Aligos Therapeutics
- Arrowhead Pharmaceuticals
- Bristol Myer Squibb
- Fujirebio Incorporation
- Immunocore
- Merck Sharp and Dohme
Zitieren
APA
Mak, L. Y., Hui, R. W., Fung, J., Seto, W. K., & Yuen, M. F. (2023). The role of different viral biomarkers on the management of chronic hepatitis B. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2022.0448
Vancouver
Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. The role of different viral biomarkers on the management of chronic hepatitis B. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2022.0448
BibTeX
@article{Mak2023,
author = {Mak, Lung-Yi and Hui, Rex Wan-Hin and Fung, James and Seto, Wai Kay and Yuen, Man-Fung},
title = {The role of different viral biomarkers on the management of chronic hepatitis B},
journal = {Clinical and Molecular Hepatology},
year = {2023},
doi = {10.3350/cmh.2022.0448}
}
EUVIMED